Active surveillance in intermediate risk prostate cancer: is it safe? Opinion: No

Nishanth Krishnananthan¹, Nathan Lawrentschuk^{1

2

3}

Affiliations

¹ University of Melbourne, Department of Surgery, Austin Health, Melbourne, Australia.
² Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
³ Olivia Newton-John Cancer Research Institute, Melbourne, Australia.

Nishanth Krishnananthan et al. Int Braz J Urol. 2016 May-Jun.

. 2016 May-Jun;42(3):418-21.

doi: 10.1590/S1677-5538.IBJU.2016.03.04.

Nishanth Krishnananthan¹, Nathan Lawrentschuk^{1

2

3}

¹ University of Melbourne, Department of Surgery, Austin Health, Melbourne, Australia.
² Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
³ Olivia Newton-John Cancer Research Institute, Melbourne, Australia.

No abstract available

References

1. Welty CJ, Cooperberg MR, Carroll PR. Meaningful end points and outcomes in men on active surveillance for early-stage prostate cancer. Curr Opin Urol. 2014;24:288–292. - PMC - PubMed
1. Klotz L. Active surveillance: the Canadian experience with an “inclusive approach”. J Natl Cancer Inst Monogr. 2012;2012:234–241. - PMC - PubMed
1. Weerakoon M, Papa N, Lawrentschuk N, Evans S, Millar J, Frydenberg M, et al. The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian Prostate Cancer Registry. BJU Int. 2015;115:50–56. - PubMed
1. Cristea O, Lavallée LT, Montroy J, Stokl A, Cnossen S, Mallick R, et al. Active surveillance in Canadian men with low-grade prostate cancer. CMAJ. 2016 Feb 29; Epub ahead of print. - PMC - PubMed
1. Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33:272–277. - PubMed